Pfizer (PFE) : On Monday, The money flowed into the Pfizer (PFE) stock with an uptick to downtick ratio was recorded at 1.6. Transactions worth $125.88 million were done on upticks, confirming the buying interest in the stock. The outflow of money on downticks stood at $78.59 million. The total money flow into the stock was $47.29 million. The block trades reveal a bullish bias with an up-down ratio of 4.93. The investors are using every small weakness in the stock to accumulate it, as can be seen in the $64.99 million of block transactions on upticks. The value of block trades on downticks was $13.19 million, indicating lower selling interest. The total money flow in block trades was $51.8 million. In terms of price action, Pfizer (PFE) traded down $0.17 during the session at $34.98. Compared to the previous days closing, the stock was down only by -0.48%. For the week, the stock is -1.3%, over previous weeks closing.
Shares of Pfizer Inc. appreciated by 0.52% during the last five trading days but lost 3.72% on a 4-week basis. Pfizer Inc. is up 6.06% in the last 3-month period. Year-to-Date the stock performance stands at 11.77%.
Pfizer (NYSE:PFE): During Mondays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $35.05 and $34.93 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $35.17. The buying momentum continued till the end and the stock did not give up its gains. It closed at $35.11, notching a gain of 0.37% for the day. The total traded volume was 12,354,034 . The stock had closed at $34.98 on the previous day.
In a related news,The officer (Executive Vice President) of Pfizer Inc, Damelio Frank A sold 100,000 shares at $34.49 on May 26, 2016. The Insider selling transaction had a total value worth of $3,449,000. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its products include Lyrica, the Prevnar family of products, Enbrel, Celebrex, Lipitor, Viagra, Zyvox, Sutent, EpiPen, Toviaz, Tygacil, Rapamune, Xalkori, Inlyta, Norvasc, BeneFIX, Genotropin and Enbrel, among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP), Global Vaccines, Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing, registering and commercializing medications in therapeutic areas, such as inflammation, cardiovascular/metabolic, neuroscience and pain, rare diseases and womens/mens health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira, Inc.